94 papers
Pharmacology and toxicology explore how substances interact with living systems, ranging from the development of life-saving medicines to understanding the dangers of chemical exposure. This field sits at the critical intersection of chemistry and biology, asking essential questions about how drugs work, how the body processes them, and what happens when things go wrong. It is a dynamic area where researchers constantly strive to improve patient safety while discovering new therapeutic possibilities.
At Gist.Science, we bridge the gap between complex research and public understanding by curating the latest preprints from bioRxiv in this vital category. Our team processes every new submission from bioRxiv as it appears, transforming dense scientific data into both plain-language overviews and detailed technical summaries. This ensures that whether you are a specialist or a curious reader, you can grasp the significance of these emerging findings without getting lost in jargon.
Below are the most recent pharmacology and toxicology papers from bioRxiv, each accompanied by our expert analysis to help you navigate the latest scientific breakthroughs.
This study demonstrates that model ensembling and machine learning approaches significantly outperform standard dosing and single-model methods in predicting the optimal first dose of amoxicillin for intensive care patients, thereby enhancing target attainment without requiring initial concentration measurements.
Asarinin inhibits RANKL-induced osteoclast differentiation and actin ring formation by selectively targeting the p38/ERK-c-Fos-NFATc1 signaling axis, suggesting its potential as a therapeutic agent for pathological bone loss.
This study demonstrates that the muscarinic antagonist KH-5 functions as a dualsteric ligand with mixed orthosteric and allosteric mechanisms at M1 receptors, while acting primarily as a competitive antagonist at M2 receptors, offering a new framework for developing subtype-selective anticholinergic drugs.
This study demonstrates that methyl carnosate, a rosemary-derived diterpene, effectively inhibits RANKL-induced osteoclastogenesis and NF-κB signaling with greater potency than carnosic acid, highlighting its potential as a therapeutic lead for treating bone-destructive diseases.